KDM3B Antibody / Lysine-specific demethylase 3B Antibody (FY13605)

KDM3B Antibody by IF in HeLa cells. Immunofluorescence staining of HeLa cells using Lysine-specific demethylase 3B Antibody reveals prominent green nuclear staining with red alpha-tubulin labeling of the cytoplasm. Nuclei were counterstained with DAPI (blue). The observed distribution is described from the fluorescence image without claiming organelle-specific colocalization in the absence of an appropriate marker.

KDM3B Antibody by IHC in human lung carcinoma. Immunohistochemistry of paraffin-embedded human lung carcinoma using Lysine-specific demethylase 3B Antibody reveals brown immunoreactivity in malignant epithelial structures and some surrounding cells. Sections underwent heat-mediated antigen retrieval in EDTA buffer (pH 8.0), blocking with goat serum, and primary antibody incubation at 2 ug/mL overnight at 4oC. Bound antibody was detected using an HRP-conjugated secondary antibody and DAB chromogen.

KDM3B Antibody by FACS in HEL cells. Flow cytometry of fixed, permeabilized HEL cells stained with Lysine-specific demethylase 3B Antibody shows a rightward fluorescence shift (blue) relative to the rabbit IgG isotype control (green) and unstained control (red). Cells were fixed in 4% paraformaldehyde, stained with 1 ug antibody per 1 x 10^6 cells, and detected with a fluorophore-conjugated secondary antibody. The experiment evaluates intracellular immunoreactivity, not cell-surface expression.

KDM3B Antibody by WB in human leukemia cell lines. Western blot analysis using Lysine-specific demethylase 3B Antibody detects a prominent immunoreactive band near 210 kDa in K562 (lane 1) and HEL (lane 2) whole-cell lysates. The observed migration is compared with the calculated molecular weight of approximately 192 kDa. Reduced lysates containing 30 ug protein per lane were separated by 8% SDS-PAGE and transferred to nitrocellulose. After blocking with 5% nonfat milk, the membrane was incubated with primary antibody at 0.5 ug/mL overnight at 4oC, followed by HRP-conjugated secondary antibody and chemiluminescent detection.